Results 211 to 220 of about 103,809 (257)

Redefining CHI3L1: Therapeutic Opportunities at the Crossroads of Immune Suppression and Disease Progression

Medicinal Research Reviews, EarlyView.
ABSTRACT Chitinase‐3‐like‐1 (CHI3L1, also known as YKL‐40) has been recognized as a biomarker of inflammation and tissue remodeling and has now emerged as a pseudoenzymatic immune checkpoint. Recent structural, immunological, and translational studies redefine it as an active regulator of immune suppression rather than a passive disease marker. Despite
Kirti Upmanyu, Saurabh Upadhyay, Moustafa T. Gabr   +2 more
wiley   +1 more source

Late INa as a Therapeutic Target: New Strategies, Computational Modelling, Drug Development, and Clinical Translation

Medicinal Research Reviews, EarlyView.
ABSTRACT The Nav1.5 channel, a major isoform of voltage‐gated sodium ion channel, is mainly found in ventricular cardiomyocytes, playing a key role in generating essential cardiac action potentials for normal heart rhythms. Mutations in Nav1.5 have been associated with severe heart conditions such as long QT syndrome, Brugada syndrome, cardiac ...
Arkapravo Chattopadhyay, Lynn C. Lunsonga, Peter E. Light, Khaled Barakat   +3 more
wiley   +1 more source

Navigating the Complexity: A Comprehensive Review of GSK‐3 Inhibition in Regenerative Medicine

Medicinal Research Reviews, EarlyView.
ABSTRACT Glycogen synthase kinase‐3 (GSK‐3) is a central regulator of numerous cellular signaling pathways, with critical roles in metabolism, proliferation, differentiation, and tissue regeneration. This review explores the multifaceted effects of pharmacological GSK‐3 inhibition across multiple body districts, focusing on its highly context‐dependent
Davide Schiroli, Alessia Merra, Chiara Marraccini, Lucia Merolle, Graziella Pellegrini, Eleonora Maurizi   +5 more
wiley   +1 more source

Accelerating virtual patient generation with a Bayesian optimization and machine learning surrogate model

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 486-494, March 2025.
Abstract The pharmaceutical industry has increasingly adopted model‐informed drug discovery and development (MID3) to enhance productivity in drug discovery and development. Quantitative systems pharmacology (QSP), which integrates drug action mechanisms and disease complexities to predict clinical endpoints and biomarkers is central to MID3.
Hiroaki Iwata, Ryuta Saito
wiley   +1 more source

Multitarget Regulatory Mechanisms and Research Advances of Plant‐Derived Bioactive Ingredients in Hypertension Prevention and Management

Phytotherapy Research, EarlyView.
Schematic overview of the multi‐target and multi‐pathway mechanisms of PDBI in the prevention and management of hypertension. ABSTRACT Hypertension remains a major global risk factor for cardiovascular diseases, yet current treatments face challenges such as suboptimal blood pressure control and inadequate organ protection.
Qiqi Deng, Yonglin Zhang, Jing Pan, Jing Luo, Hualin Sun, Chaonian Li, Li Li   +6 more
wiley   +1 more source

Identification of a Novel De Novo HECW2 Gene Pathogenic Variant in a Fetus With Cardiac Abnormalities

Prenatal Diagnosis, EarlyView.
Kristina Nimchenko, Bettina Bessieres, Gihad E. Chalouhi, Antonia Pop, Vanina Castaigne, Bertrand Stos, Marie‐Paule Beaujard, Diane Roy, Daniela Laux, Tania Attie‐Bitach   +9 more
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Measuring hypertrophy in neonatal rat primary cardiomyocytes and human iPSC-derived cardiomyocytes

Methods, 2022
In the heart, left ventricular hypertrophy is initially an adaptive mechanism that increases wall thickness to preserve normal cardiac output and function in the face of coronary artery disease or hypertension. Cardiac hypertrophy develops in response to pressure and volume overload but can also be seen in inherited cardiomyopathies.
Kyla, Bourque, Cara, Hawey, Jace, Jones-Tabah, Darlaine, Pétrin, Ryan D, Martin, Yi, Ling Sun, Terence E, Hébert   +6 more
openaire   +2 more sources

Isolation and Differentiation of Human Cardiomyocyte Progenitor Cells into Cardiomyocytes

2012
To date, there is no suitable in vitro model to study human adult cardiac cell biology. Here, we describe a method for efficient isolation and expansion of human cardiomyocyte progenitor cells (CMPCs) from cardiac surgical waste or, alternatively, from fetal heart tissue.
Anke M, Smits, Angelique A, van Oorschot, Marie-José, Goumans   +2 more
openaire   +4 more sources

The human adult cardiomyocyte phenotype

Cardiovascular Research, 2003
Determination of the phenotype of adult human atrial and ventricular myocytes based on gene expression and morphology.Atrial and ventricular cardiomyocytes were obtained from patients undergoing cardiac surgery using a modified isolation procedure. Myocytes were isolated and cultured with or without serum.
Bird, SD, Doevendans, PA, van Rooijen, MA, de la Riviere, AB, Hassink, RJ, Passier, R, Mummery, CL   +6 more
openaire   +3 more sources

Adult human cardiomyocyte mechanics in osteogenesis imperfecta

American Journal of Physiology-Heart and Circulatory Physiology, 2023
In a rare donation of a heart from an individual with osteogenesis imperfecta (OI), we explored cardiomyocyte (CM) adaptations to low stiffness. This represents the first assessment of cardiomyocyte mechanics in OI. The data reveal the hypercontractility of OI CMs with rapid rundown when exposed to acute stiffness challenges, extending our ...
Benjamin W. Lee, Matthew A. Caporizzo, Christina Y. Chen, Kenneth C. Bedi, Eliot G. Peyster, Benjamin L. Prosser, Kenneth B. Margulies, Alexia Vite   +7 more
openaire   +4 more sources